2-year remission of type 2 diabetes and pancreas morphology: a post-hoc analysis of the DiRECT open-label, cluster-randomised trial

被引:81
|
作者
Al-Mrabeh, Ahmad [1 ]
Hollingsworth, Kieren G. [1 ]
Shaw, James A. M. [2 ]
McConnachie, Alex [3 ]
Sattar, Naveed [4 ]
Lean, Michael E. J. [5 ]
Taylor, Roy [1 ]
机构
[1] Newcastle Univ, Magnet Resonance Ctr, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England
[2] Newcastle Univ, Regenerat Med, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England
[3] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland
[4] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland
[5] Univ Glasgow, Sch Med Dent & Nursing, Glasgow, Lanark, Scotland
来源
LANCET DIABETES & ENDOCRINOLOGY | 2020年 / 8卷 / 12期
关键词
D O I
10.1016/S2213-8587(20)30303-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The pancreas is small and irregular in shape in people with type 2 diabetes. If these abnormalities are caused by the disease state itself rather than being a predisposing factor, remission of type 2 diabetes should restore normal pancreas morphology. The objective of this study was to determine whether changes in pancreas volume and shape occurred during 2 years of remission. Methods For this post-hoc analysis, we included a subset of adult participants of the Diabetes Remission Clinical Trial (DiRECT), who had type 2 diabetes and were randomly assigned to a weight management intervention or routine diabetes management. Intervention group participants were categorised as responders (HbA(1c) <6.5% [48 mmol/mol] and fasting blood glucose <7.0 mmol/L, off all anti-diabetes medication) and non-responders, who were classified as remaining diabetic. Data on pancreas volume and irregularity of pancreas border at baseline, 5 months, 12 months, and 24 months after intervention were compared between responders and non-responders; additional comparisons were made between control group participants with type 2 diabetes and a non-diabetic comparator (NDC) group, who were matched to the intervention group by age, sex, and post-weight-loss weight, to determine the extent of any normalisation. We used a mixed-effects regression model based on repeated measures ANOVA with correction for potential confounding. Magnetic resonance techniques were employed to quantify pancreas volume, the irregularity of the pancreas borders, and intrapancreatic fat content. beta-cell function and biomarkers of tissue growth were also measured. Findings Between July 25, 2015, and Aug 5, 2016, 90 participants with type 2 diabetes in the DiRECT subset were randomly assigned to intervention (n=64) or control (n=26) and were assessed at baseline; a further 25 non-diabetic participants were enrolled into the NDC group. At baseline, mean pancreas volume was 61.7 cm(3) (SD 16.0) in all participants with type 2 diabetes and 79.8 cm(3) (14.3) in the NDC group (p<0.0001). At 24 months, pancreas volume had increased by 9.4 cm(3) (95% CI 6.1 to 12.8) in responders compared with 6.4 cm(3) (2.5 to 10.3) in non-responders (p=0.0008). Pancreas borders at baseline were more irregular in participants with type 2 diabetes than in the NDC group (fractal dimension 1.138 [SD 0.027] vs 1.097 [0.025]; p<0.0001) and had normalised by 24 months in responders only (1.099 [0.028]). Intrapancreatic fat declined by 1.02 percentage points (95% CI 0.53 to 1.51) in 32 responders and 0.51% (-0.17 to 1.19) in 13 non-responders (p=0.23). Interpretation These data show for the first time, to our knowledge, reversibility of the abnormal pancreas morphology of type 2 diabetes by weight loss-induced remission. Copyright (C) 2020 Elsevier Ltd. All rights reserved.
引用
下载
收藏
页码:939 / 948
页数:10
相关论文
共 50 条
  • [21] Effectiveness of a mobile phone text messaging intervention on dietary behaviour in patients with type 2 diabetes: a post-hoc analysis of a randomised controlled trial
    Islam, Sheikh Mohammed Shariful
    George, Elena S.
    Maddison, Ralph
    MHEALTH, 2021, 7 (01)
  • [22] The Predictive Factors of Weight Loss Induced by Metformin on Newly Diagnosed Type 2 Diabetes: Post Hoc Analysis from Data of a Phase IV Open-Label Trial
    Zhou, Lingli
    Han, Xueyao
    Cai, Xiaoling
    Ji, Linong
    DIABETES, 2015, 64 : A658 - A658
  • [23] Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study
    Waldman, Boris
    Ansquer, Jean-Claude
    Sullivan, David R.
    Jenkins, Alicia J.
    McGill, Neil
    Buizen, Luke
    Davis, Timothy M. E.
    Best, James D.
    Li, Liping
    Feher, Michael D.
    Foucher, Christelle
    Kesaniemi, Y. Antero
    Flack, Jeffrey
    d'Emden, Michael C.
    Scott, Russell S.
    Hedley, John
    Gebski, Val
    Keech, Anthony C.
    LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (04): : 310 - 318
  • [24] Change in cardiovascular risk factors following early diagnosis of type 2 diabetes: a cohort analysis of a cluster-randomised trial
    Black, James A.
    Sharp, Stephen J.
    Wareham, Nicholas J.
    Sandbaek, Annelli
    Rutten, Guy E. H. M.
    Lauritzen, Torsten
    Khunti, Kamlesh
    Davies, Melanie J.
    Borch-Johnsen, Knut
    Griffin, Simon J.
    Simmons, Rebecca K.
    BRITISH JOURNAL OF GENERAL PRACTICE, 2014, 64 (621): : E208 - E216
  • [25] Effect on neonatal sepsis following immediate kangaroo mother care in a newborn intensive care unit: a post-hoc analysis of a multicentre, open-label, randomised controlled trial
    Arya, Sugandha
    Chhabra, Suhail
    Singhal, Richa
    Kumari, Archana
    Wadhwa, Nitya
    Anand, Pratima
    Naburi, Helga
    Kawaza, Kondwani
    Newton, Sam
    Adejuyigbe, Ebunoluwa
    Westrup, Bjorn
    Bergman, Nils
    Rettedal, Siren
    Linner, Agnes
    Chauhan, Rahul
    Rani, Nisha
    Minckas, Nicole
    Yoshida, Sachiyo
    Rao, Suman
    Chellani, Harish
    ECLINICALMEDICINE, 2023, 60
  • [26] Improvements in storage and voiding symptoms with dutasteride, tamsulosin and the combination:: Post-hoc analysis of the 2-year data from the combat trial
    Becher, Edgardo F.
    Roehrborn, Claus G.
    Siami, Paul
    Major-Walker, Kim
    Wilson, Timothy H.
    Montorsi, Francesco
    JOURNAL OF UROLOGY, 2008, 179 (04): : 698 - 699
  • [27] The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program
    Li, JingWei
    Badve, Sunit, V
    Zhou, Zien
    Rodgers, Anthony
    Day, Richard
    Oh, Richard
    Lee, Mary
    Perkovic, Vlado
    de Zeeuw, Dick
    Mahaffey, Kenneth W.
    Futcher, Greg
    Matthews, David R.
    Neal, Bruce
    LANCET RHEUMATOLOGY, 2019, 1 (04): : E220 - E228
  • [28] Efficacy and safety of repaglinide added to sitagliptin in Japanese patients with type 2 diabetes: a randomised 24 week open-label trial
    Nishimura, A.
    Usui, S.
    Kumashiro, N.
    Uchino, H.
    Yamato, A.
    Yasuda, D.
    Okubo, M.
    Mori, Y.
    Hirose, T.
    DIABETOLOGIA, 2015, 58 : S345 - S345
  • [29] EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinsons Disease
    Tanner, Caroline M.
    Pahwa, Rajesh
    Hauser, Robert A.
    Oertel, Wolfgang H.
    Isaacson, Stuart H.
    Jankovic, Joseph
    Johnson, Reed
    Chernick, Dustin
    Hubble, Jean
    JOURNAL OF PARKINSONS DISEASE, 2020, 10 (02) : 543 - 558
  • [30] Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label multicentre, randomised, phase 3 trial
    Zoellner, Anna-Katharina
    Unterhalt, Michael
    Stilgenbauer, Stephan
    Huebel, Kai
    Thieblemont, Catherine
    Metzner, Bernd
    Topp, Max
    Truemper, Lorenz
    Schmidt, Christian
    Bouabdallah, Kamal
    Krauter, Juergen
    Lenz, Georg
    Duerig, Jan
    Vergote, Vibeke
    Schaefer-Eckart, Kerstin
    Andre, Marc
    Kluin-Nelemans, Hanneke C.
    van Hoof, Achiel
    Klapper, Wolfram
    Hiddemann, Wolfgang
    Dreyling, Martin
    Hoster, Eva
    LANCET HAEMATOLOGY, 2021, 8 (09): : E648 - E657